On September 8, the Chief Executive Officer of Sino Biopharm (1177.HK) was invited to attend the 32nd CITIC CLSA Investors' Forum and delivered a speech titled "Sino Biopharm: A Leading Innovation-Driven Pharmaceutical Company," systematically elaborating on the company's achievements and plans in strategic transformation, R&D innovation, and global layout. This forum brought together global industry experts, corporate executives, and top analysts to discuss investment trends and industry dynamics.

On September 8, the 25th China International Fair for Investment & Trade (CIFIT) grandly opened in Xiamen.

On September 6, Zhang Xiang, President of The University of Hong Kong, led a delegation to visit Chia Tai Tianqing, a core enterprise of Sino Biopharm. The delegation included Vice President Lin Chen of The University of Hong Kong and renowned entrepreneurs such as Wang Jianguo, Chairman of Five Star Holdings; Fan Min, Co-founder of Ctrip.com; Wang Zhihan, Chairman of the Board of Goheal Group; and Yang Xiao, Chairman of Renhe Pharmacy Co., Ltd.

On the morning of September 3, a grand ceremony commemorating the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War was held in Tiananmen Square, Beijing.

Recently, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a core enterprise of Sino Biopharm, has completed the first shipment for the Named Patient Program (NPP) of Caring Pharma Partner in collaboration with the Greater China Cancer Foundation (hereinafter referred to as "the Foundation"). A batch of innovative anti-cancer drugs, carrying the hope of life, was dispatched from Chia Tai Tianqing and successfully arrived in Hong Kong.

On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.

Recently, the website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China announced that LM-302, a Class 1 new drug independently developed by LaNova Medicines, a wholly-owned subsidiary of Sino Biopharm, is proposed for inclusion in the Breakthrough Therapy Designation (BTD) program. The indication is for first-line treatment of CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in combination with Toripalimab.

Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharm (01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.

China Securities Journal, cs.com.cn (Reporter: Meng Peijia) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion in the first half of the year, representing year-on-year increases of 10.7% and 140.2%, respectively, achieving double-digit performance growth. The company proposes to distribute a dividend of RMB 820 million for the first half of 2025, an increase of over 60% compared to the same period last year.

Xinhua Finance, Nanjing, August 18 (Reporter: Zhu Cheng) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively.